--- title: "Hong Kong Stock Movement: XUANZHUBIO-B Rises 16%! Clear Capital Flow, Market Sentiment Triggers Volatility Attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/286730971.md" description: "XUANZHUBIO-B rose 16.00%; CSPC Pharmaceutical Group fell 2.57%, with a transaction volume of HKD 422 million; China Biologic Products fell 1.67%, with a transaction volume of HKD 222 million; Hansoh Pharmaceutical fell 2.90%, with a transaction volume of HKD 180 million; Heng Rui Medicine fell 4.18%, with a market value of HKD 417.8 billion" datetime: "2026-05-18T07:31:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286730971.md) - [en](https://longbridge.com/en/news/286730971.md) - [zh-HK](https://longbridge.com/zh-HK/news/286730971.md) --- # Hong Kong Stock Movement: XUANZHUBIO-B Rises 16%! Clear Capital Flow, Market Sentiment Triggers Volatility Attention **Hong Kong Stock Movement** XUANZHUBIO-B, up 16.00%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Transaction Volume** CSPC Pharmaceutical Group down 2.57%. Based on recent news, 1. On May 15, CSPC Pharmaceutical Group experienced personnel turmoil, which is essentially a short-term manifestation during the company's transformation period. Under the leadership of the second generation, CSPC is transforming from a traditional pharmaceutical company to a global innovation giant, with adjustments aimed at adapting to industry changes and enhancing risk resistance. This change has attracted market attention, leading to stock price fluctuations. Source: Zhitong Finance 2. On May 15, the pharmaceutical industry is undergoing structural reshuffling, with centralized procurement eliminating backward production capacity, and innovation and internationalization becoming survival paths. CSPC actively embraces change, adapting its strategic transformation through organizational innovation to enhance foresight and risk resistance. This industry dynamic affects CSPC's stock price. Source: Zhitong Finance 3. On May 15, the youth-oriented, professional, and international team led by Cai Lei is breaking down traditional management barriers in pharmaceutical companies. The core team combines local experience with a global perspective, driving CSPC's innovation pipeline and international layout into a harvest period. This team change affects market confidence, leading to stock price fluctuations. Source: Zhitong Finance. The trend of innovation and internationalization in the pharmaceutical industry is evident. China Biologic Products Holdings down 1.67%. Based on recent key news: 1. On May 15, China Biologic Products announced the repurchase of 1.87 million shares, costing HKD 10.0269 million. This move aims to enhance market confidence but failed to stop the stock price decline, reflecting market concerns about the company's future performance. Source: Zhitong Finance. The Hong Kong stock market has recently seen increased volatility, and risks need to be monitored. Hansoh Pharmaceutical down 2.90%. Based on recent key news: 1. On May 15, Hansoh Pharmaceutical announced the resignation of co-secretary Li Liangxian, with Ms. Zeng Zhao taking over. This personnel change may raise market concerns about corporate governance, leading to a stock price decline. Source: Zhitong Finance 2. On May 15, Hansoh Pharmaceutical issued an announcement through the Hong Kong Stock Exchange, emphasizing the company's responsibility for information disclosure. This move may affect investors' confidence in the company's transparency, further exacerbating stock price fluctuations. Source: Hong Kong Stock Exchange 3. No other significant news recently. The pharmaceutical industry has seen considerable volatility recently, and policy changes need to be monitored. **Stocks Ranked High in Industry Market Capitalization** Hengrui Medicine down 4.18%. Based on recent key news: 1. On May 15, Hengrui Medicine's subsidiary, Ruishi Biopharmaceutical, received approval from the National Medical Products Administration for the clinical trial approval notice regarding RSS0393 latex, which will commence clinical trials soon. This news failed to boost the stock price and instead led to a decline due to market concerns about the risks of new drug development. Source: Zhitong Finance 2. On May 15, Hengrui Medicine continues to maintain a leading position in the oncology sector, with over ten indications/products expected to be approved this year, solidifying future performance. However, market skepticism regarding the high valuation of innovative pharmaceutical companies and future profitability pressures the stock price. Source: Wall Street Insights On May 14th, the patent pool organization strengthened its business expansion in China, increasing its scale and betting on the Chinese market. Although this is beneficial for the long-term development of HengRui Medicine, it has not alleviated the pressure of the stock price decline in the short term. Source: Jinshi Data Innovative pharmaceutical companies are gaining momentum in going overseas, but risks need to be vigilant ### Related Stocks - [02575.HK](https://longbridge.com/en/quote/02575.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [01276.HK](https://longbridge.com/en/quote/01276.HK.md) ## Related News & Research - [Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong](https://longbridge.com/en/news/286072114.md) - [US Supreme Court rebuffs pharma challenge to Biden-era drug price](https://longbridge.com/en/news/286781823.md) - [Xuanzhu Biopharmaceutical Sets March 30 Board Meeting for 2025 Results and Dividend Decision](https://longbridge.com/en/news/279271433.md) - [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md) - [Lipocine Showcases Phase 3 Data for Postpartum Depression](https://longbridge.com/en/news/286923466.md)